Streetbeat News

GNPX

Genprex, Inc.

https://www.genprex.com

Industry

Biotechnology

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Open

0.40

Mkt cap

3.3M

Volume

1.3M

High

0.42

P/E Ratio

-0.04

52-wk high

5.41

Low

0.36

Div yield

N/A

52-wk low

0.28

Genprex, Inc. is advancing its diabetes program through a strategic collaboration with a CDMO to research a non-viral delivery system for its gene therapy drug candidate. This positions Genprex as a thought leader in the diabetes market.

Portfolio Pulse from

February 19, 2025 | 1:30 pm

Genprex, Inc. has advanced its diabetes gene therapy program by signing an amended license agreement with the University of Pittsburgh for multiple technologies. The company also formed a new subsidiary, Convergen Biotech, Inc., to focus on diabetes program development.

Portfolio Pulse from

February 18, 2025 | 1:30 pm

Genprex, Inc. announced promising results from a study on NPRL2 gene therapy using their Oncoprex® Delivery System, showing potential as a treatment for anti-PD1 resistant non-small cell lung cancer.

Portfolio Pulse from

February 13, 2025 | 1:30 pm

Genprex, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference, engaging in investor and business development meetings.

Portfolio Pulse from

January 06, 2025 | 2:30 pm

Genprex, Inc. has completed the Phase 1 dose escalation portion of its Acclaim-3 clinical trial for Reqorsa® Gene Therapy in combination with Tecentriq® for treating extensive stage small cell lung cancer. The Safety Review Committee has approved the trial to advance to Phase 2.

Portfolio Pulse from

December 16, 2024 | 2:30 pm

Genprex, Inc. has signed an exclusive license agreement with the University of Michigan for gene therapy technologies aimed at treating ALK-positive lung cancer. This includes the use of Genprex's Reqorsa® Gene Therapy in combination with ALK-inhibitors.

Portfolio Pulse from

November 20, 2024 | 2:45 pm

In Monday's after-market session, Shuttle Pharmaceuticals, Impact BioMedical, and Onconetix saw significant stock price increases, while TransMedics Group and Cardio Diagnostics Holdings experienced notable declines. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 8:31 pm

Genprex shares rose following the presentation of preclinical data on Reqorsa Gene Therapy, Mesothelioma, and Glioblastoma at the 2024 EORTC-NCI-AACR Symposium.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:31 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Notable gainers included Healthcare Triangle, Monte Rosa Therapeutics, and Evoke Pharma, while Sonnet BioTherapeutics and Koninklijke Philips were among the losers. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 4:30 pm

Genprex's short interest has increased by 5.38%, with 85,000 shares sold short, representing 3.33% of its float. This is below the peer group average of 3.81%. Short interest can indicate market sentiment, with rising short interest suggesting bearish sentiment.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 3:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.